Modified Rankin Scale for Neurologic Disability

Why use it

The mRS provides a globally accepted, validated, and highly reproducible measure of neurological disability after stroke. It enables comparison of outcomes across trials, facilitates triage for rehabilitation intensity, and guides patient and family counseling regarding functional prognosis. In clinical practice, serial mRS assessments track recovery and inform discharge planning and rehabilitation goals. The mRS is also used as an eligibility criterion in thrombectomy trials (e.g., pre-stroke mRS ≤1 required for inclusion in most mechanical thrombectomy RCTs).

About

The Modified Rankin Scale (mRS) is the most widely used outcome measure in stroke clinical trials and is broadly applied across neurological conditions to quantify disability and dependence in daily activities. Originally described by John Rankin in 1957 as a 6-point scale, it was subsequently modified by van Swieten and colleagues in 1988 to its current 7-point form (grades 0–6). The scale assesses the degree to which a neurological condition interferes with the patient's activities of daily living and usual social activities, anchored at one extreme by no symptoms (grade 0) and at the other by death (grade 6). The mRS is endorsed by the American Stroke Association, the European Stroke Organisation, and national stroke guidelines worldwide as the primary functional outcome metric. It is the primary endpoint in virtually all acute stroke intervention trials (e.g., tPA trials, mechanical thrombectomy trials such as MR CLEAN, DAWN, DEFUSE 3). A "good functional outcome" is typically defined as mRS ≤2 (independent), and "excellent outcome" as mRS ≤1. The scale is administered as a structured interview or clinician assessment at baseline and at predefined follow-up time points (commonly 90 days after stroke).

When to use

• Assessment of functional outcome at 90 days after ischemic or hemorrhagic stroke (primary endpoint in clinical trials)
• Pre-stroke mRS documentation before thrombolysis or thrombectomy decisions — pre-stroke mRS ≤1 is required for most endovascular trials
• Serial functional assessment during inpatient rehabilitation or outpatient follow-up to track recovery trajectory
• Documentation of baseline neurological disability in patients with chronic neurological conditions (MS, Parkinson's disease, TIA workup)
• Quality benchmarking and performance metrics in stroke units
• Prognostication and family counseling after acute neurological events

Formula

Pearls & pitfalls

• The mRS is a GLOBAL disability scale — it captures overall functional status, not individual neurological deficits. A patient can have residual neurological deficits (e.g., mild aphasia) but still be independent (mRS 1–2) if function is preserved.
• The structured interview versions of the mRS (e.g., the mRS Questionnaire, mRS-Q) improve inter-rater reliability — these should be preferred over unstructured administration in research settings.
• Inter-rater reliability of the mRS is good with training (weighted kappa 0.72–0.95) but can be poor without it — all outcome assessors in clinical trials should be certified using validated video training programs.
• The 90-day mRS is the standard primary endpoint time point in acute stroke trials, as most neurological recovery occurs within the first 3 months after ischemic stroke.
• Pre-stroke mRS should always be documented — it determines eligibility for acute interventions and contextualizes the outcome. A patient with pre-stroke mRS 3 who achieves mRS 3 at 90 days has had a "good outcome" relative to baseline.
• The distinction between mRS 2 and mRS 3 hinges on independence: mRS 2 patients can look after their own affairs WITHOUT assistance; mRS 3 patients require some help but can walk without assistance.
• mRS 4 vs mRS 5: both require assistance, but mRS 4 can walk with assistance and attend to bodily needs with some help; mRS 5 requires constant nursing care and cannot walk or attend to bodily needs unassisted.
• The mRS is increasingly used outside stroke — in subarachnoid hemorrhage, intracerebral hemorrhage, Guillain-Barré syndrome, and as a general neurological disability measure in trials of neurological conditions.
• A shift analysis (ordinal logistic regression across all mRS levels) is now the preferred statistical approach in acute stroke trials, capturing benefit across the full disability spectrum rather than a binary cutpoint.

Next steps

mRS 0–1 (No or minimal disability): Patient is functionally independent. Outpatient follow-up. Secondary prevention optimization (antiplatelet/anticoagulation, statin, blood pressure control). mRS 2 (Slight disability): Independent in most activities but some restriction. Outpatient rehabilitation (physiotherapy/occupational therapy) as appropriate. Return-to-work assessment. mRS 3 (Moderate disability): Requires some assistance. Assess for inpatient or intensive outpatient rehabilitation. Caregiver education and support. mRS 4–5 (Moderately severe to severe disability): Requires significant or total assistance. Specialist rehabilitation assessment. Discharge planning — care home vs. home with carers. mRS 6: Death.

Evidence

Rankin J. Cerebral vascular accidents in patients over the age of 60. Scot Med J. 1957;2:200-215. Van Swieten JC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607. PMID:3363593. Validated in multiple large stroke trials including NINDS tPA trial (1995), IST-3 (2012), MR CLEAN (2015), DAWN (2018), DEFUSE 3 (2018). Systematic review: Quinn TJ et al. Functional outcome measures in contemporary stroke trials. Int J Stroke. 2009;4(3):200-205. Inter-rater reliability weighted kappa 0.72–0.95 with certified video training.

References

1. Rankin J. Cerebral vascular accidents in patients over the age of 60. Scot Med J. 1957;2:200-215. — link
2. van Swieten JC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607. — link
3. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials. Stroke. 2007;38(3):1091-1096. — link
4. Quinn TJ et al. Functional outcome measures in contemporary stroke trials. Int J Stroke. 2009;4(3):200-205. — link
5. Lees KR et al. (MR CLEAN investigators). Time to treatment with intravenous alteplase and outcome in stroke. JAMA. 2016;315(19):2046-2054. — link